Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 16/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 11/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 11/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 11/20 | 0.46 |
| ▸ | PIK3R1 | P27986 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1858759 | 0.89 | PIK3CA (0.47) | SMN1; SMN2PIK3CAPIK3R1MTOR | |
| SCHEMBL1860315 | 0.86 | PIK3CA (0.45) | SMN1; SMN2PIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL1861694 | 0.85 | PIK3CA (0.53) | SMN1; SMN2PIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL1284930 | 0.84 | PIK3CA (0.52) | SMN1; SMN2PIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL1863634 | 0.82 | PIK3CA (0.47) | SMN1; SMN2PIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL1857072 | 0.82 | MEN1 (0.49) | SMN1; SMN2PIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL1686561 | 0.82 | PIK3CA (0.45) | SMN1; SMN2PIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL30130757 | 0.82 | PIK3CA (0.45) | SMN1; SMN2PIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL1857681 | 0.81 | PIK3CA (0.46) | SMN1; SMN2PIK3CAPIK3R1MEN1KMT2A | |
| SCHEMBL19849046 | 0.79 | SMN1; SMN2 (0.49) | SMN1; SMN2PIK3CAPIK3CDPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2046799-B1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GENENTECH INC (US) | 2017-07-19 | — | — | EP | disclosed |
| US-8450315-B2 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20110105464-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2011-05-05 | — | — | US | disclosed |
| US-7846929-B2 | Using 1-(4-((2-(aminopyrimidin-5-yl)-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-(methylsulfonyl)ethanone; lipid kinase inhibitor; anticancer agents ; antiinflammatory agents; antidiabetic agents | GENENTECH, INC. (US) | 2010-12-07 | — | — | US | disclosed |
| US-20080039459-A1 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | PLRAMED LIMITED (GB) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105464-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | PI4KB, PIK3CB, PIK3C2B | SMN1; SMN2 1342/4885PIK3CA 6/4885PIK3CD 10/4885 |
| US-20080039459-A1 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | PIK3CA, PI4KB, PI4KA | SMN1; SMN2 1774/4885PIK3CA 1/4885PIK3CD 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.